Education
About Us
Working with TipRanks
Follow Us
Regeneron Pharmaceuticals (GB:0R2M)
:0R2M
0R2M Analyst Ratings
Strong Buy
17 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0R2M Stock 12 Month Forecast
Average Price Target
$876.40
▲(48.19% Upside)
| Highest Price Target$1,120 | Average Price Target$876.40 | Lowest Price Target$547.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wells Fargo
Reiterated
04/23/25
Truist Financial
Reiterated
04/23/25
TD Cowen
Reiterated
04/23/25
Canaccord Genuity
Reiterated
04/22/25
Cantor Fitzgerald
Initiated
04/21/25
Oppenheimer
Reiterated
04/21/25
Bank of America Securities
Reiterated
04/17/25
BMO Capital
Reiterated
04/17/25
Leerink Partners
Reiterated
04/14/25
Goldman Sachs
Reiterated
04/11/25
Citi
$750→$600
Hold
1.45%
Upside
Reiterated
04/11/25
Regeneron Pharma (REGN) PT Lowered to $600 at CitiCiti analyst Geoff Meacham lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $600.00 (from $750.00) while maintaining a Neutral rating.
Guggenheim
$950→$940
Buy
58.94%
Upside
Reiterated
04/10/25
Regeneron price target lowered to $940 from $950 at GuggenheimRegeneron price target lowered to $940 from $950 at Guggenheim
Morgan Stanley
$1,150→$1,081
Buy
82.78%
Upside
Reiterated
04/09/25
Morgan Stanley Sticks to Its Buy Rating for Regeneron (REGN)
Bernstein
$1,010→$979
Buy
65.53%
Upside
Reiterated
04/03/25
Regeneron Pharma (REGN) PT Lowered to $979 at Bernstein Amid Eylea HeadwindsBernstein SocGen Group analyst William Pickering lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $979.00 (from $1,010.00) while maintaining an Outperform rating.
RBC Capital
$1,045→$1,051
Buy
77.71%
Upside
Reiterated
04/03/25
Regeneron Pharma (REGN) PT Raised to $1,051 at RBC CapitalRBC Capital analyst Brian Abrahams raised the price target on Regeneron Pharma (NASDAQ: REGN) to $1,051.00 (from $1,045.00) while maintaining a Outperform rating.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
Reiterated
04/23/25
Truist Financial
Reiterated
04/23/25
TD Cowen
Reiterated
04/23/25
Canaccord Genuity
Reiterated
04/22/25
Cantor Fitzgerald
Initiated
04/21/25
Oppenheimer
Reiterated
04/21/25
Bank of America Securities
Reiterated
04/17/25
BMO Capital
Reiterated
04/17/25
Leerink Partners
Reiterated
04/14/25
Goldman Sachs
Reiterated
04/11/25
Citi
$750→$600
Hold
1.45%
Upside
Reiterated
04/11/25
Regeneron Pharma (REGN) PT Lowered to $600 at CitiCiti analyst Geoff Meacham lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $600.00 (from $750.00) while maintaining a Neutral rating.
Guggenheim
$950→$940
Buy
58.94%
Upside
Reiterated
04/10/25
Regeneron price target lowered to $940 from $950 at GuggenheimRegeneron price target lowered to $940 from $950 at Guggenheim
Morgan Stanley
$1,150→$1,081
Buy
82.78%
Upside
Reiterated
04/09/25
Morgan Stanley Sticks to Its Buy Rating for Regeneron (REGN)
Bernstein
$1,010→$979
Buy
65.53%
Upside
Reiterated
04/03/25
Regeneron Pharma (REGN) PT Lowered to $979 at Bernstein Amid Eylea HeadwindsBernstein SocGen Group analyst William Pickering lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $979.00 (from $1,010.00) while maintaining an Outperform rating.
RBC Capital
$1,045→$1,051
Buy
77.71%
Upside
Reiterated
04/03/25
Regeneron Pharma (REGN) PT Raised to $1,051 at RBC CapitalRBC Capital analyst Brian Abrahams raised the price target on Regeneron Pharma (NASDAQ: REGN) to $1,051.00 (from $1,045.00) while maintaining a Outperform rating.
Best Analysts Covering Regeneron
Which Analyst Should I Follow If I Want to Buy GB:0R2M and Sell After:
1 Month
xxx
Success Rate
23/41 ratings generated profit
Average Return
+1.11%
assigned a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.10% of your transactions generating a profit, with an average return of +1.11% per trade.
3 Months
xxx
Success Rate
23/41 ratings generated profit
Average Return
+2.29%
assigned a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.10% of your transactions generating a profit, with an average return of +2.29% per trade.
1 Year
Success Rate
27/41 ratings generated profit
Average Return
+10.34%
assigned a buy rating 3 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 65.85% of your transactions generating a profit, with an average return of +10.34% per trade.
2 Years
xxx
Success Rate
13/20 ratings generated profit
Average Return
+13.33%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 65.00% of your transactions generating a profit, with an average return of +13.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0R2M Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
7
17
21
17
15
Buy
31
21
17
19
16
Hold
9
11
9
8
4
Sell
2
3
3
2
4
Strong Sell
0
0
0
0
0
total
49
52
50
46
39
Each month's total comprises the sum of three months' worth of ratings.
0R2M Financial Forecast
0R2M Stock Forecast FAQ
What is GB:0R2M’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 876.40.
What is GB:0R2M’s upside potential, based on the analysts’ average price target?
Regeneron Pharmaceuticals has 48.19% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Regeneron Pharmaceuticals a Buy, Sell or Hold?
Regeneron Pharmaceuticals has a consensus rating of Strong Buy, which is based on 17 buy ratings, 3 hold ratings and 1 sell ratings.
What is Regeneron Pharmaceuticals’s share price target?
The average share price target for Regeneron Pharmaceuticals is 876.40. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $1,120.00 ,and the lowest forecast is $547.00. The average share price target represents 48.19% Increase from the current price of $591.42.
The highest analyst share price target is $1,120.00 ,and the lowest forecast is $547.00. The average share price target represents 48.19% Increase from the current price of $591.42.
What do analysts say about Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
How can I buy shares of Regeneron Pharmaceuticals?
To buy shares of GB:0R2M, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.